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Summary Purpose Given distinct mechanism of actions of
enzastaurin and bevacizumab, preclinical studies suggest en-
hanced antitumor activity in combination. This phase I study
assessed the combination’s safety and efficacy. Patients and
methods Six advanced cancer patients could be enrolled in
each of 11 cohorts. Patients received an enzastaurin loading
dose. Oral enzastaurin (500 mg once daily [QD], 250mg twice
daily [BID], 375 mg BID, 500 mg BID, and 750 mg BID) was
escalated in each cohort in combination with bevacizumab
dosed at 5 mg/kg every 2 weeks, 10 mg/kg every 2 weeks, or
15 mg/kg every 3 weeks until a dose-limiting toxicity (DLT)
occurred in 2 of 6 patients in any cohort. Results Sixty-seven
patients (31, ovarian cancer [ovcar]) were evaluable for safety
and efficacy. Six treatment-related DLTs occurred: grade 3
fatigue (n04), grade 4 cerebral hemorrhage, and grade 3
elevated aspartate transaminase. Common drug-related toxic-
ities included change in color of urine and stool, fatigue, pain,
diarrhea, and nausea. The maximum tolerated dose of enzas-
taurin was 750 mg BID in combination with any tested bev-
acizumab dose/schedule. Overall response rate was 19.4 %
(32.3 % ovcar). Median time to progression was 3.7 months
(95 % confidence interval [CI], 2.7–5.5), with 8.3 months
(95 % CI, 3.7–11.1) in ovcar. Overall, 35.9 % (50.4 % ovcar)
of patients remained without disease progression after
6 months. Conclusion The recommended phase II doses of
enzastaurin were 500 mg QD up to 500 mg BID with any
tested dose/schedule of bevacizumab. This combination dem-
onstrated encouraging clinical activity, particularly in ovcar.
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Introduction
Enzastaurin HCL (enzastaurin, LY317615) was developed as
a selective PKCβ inhibitor [1, 2]. In cultured cancer cells,
enzastaurin has antiproliferative and antiapoptotic activities
[2]. Enzastaurin has antiangiogenic activity [3]. Enzastaurin
also inhibits the AKT pathway with reduced phosphorylation
of glycogen synthase kinase 3β (GSK3-β) and AKT [2].
The content was presented in part at the: Ovarian Cancer Research
Symposium (Rivken Conference), 2008; 44th Annual Meeting of the
American Society of Clinical Oncology, 2008; 45th Annual Meeting of
the American Society of Clinical Oncology, 2009; 41st Annual
Meeting of the Society of Gynecologic Oncologists, 2010.
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Vascular endothelial growth factor (VEGF) is a regulator
of blood vessel growth [4]. Bevacizumab is a humanized
anti-VEGF monoclonal antibody [4]. Because bevacizumab
and enzastaurin mechanisms of action did not appear to
overlap, we hypothesized that the combination might have
additive or synergistic effects on tumors.
This study explored whether enzastaurin could be safely
combined with bevacizumab in patients with advanced or
metastatic cancer and evaluated preliminary antitumor ac-
tivity of the combination. This study characterized enzas-
taurin pharmacokinetics (PK) when administered with
bevacizumab. Enzastaurin was administered as in previous
phase I studies and at higher doses and in different schedules
than were previously used [5–9]. Based on known activity
of bevacizumab in ovarian cancer (ovcar) [10], this study
enrolled a large proportion of patients with the disease.
Patients and methods
Eligibility
Key eligibility criteria included histologic or cytologic
diagnosis of advanced or metastatic cancer for which no
preferable therapy existed; ≥18 years of age; Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus of 0 to 2; measurable or nonmeasurable disease as
defined by Response Evaluation Criteria in Solid
Tumors (RECIST version 1.0); [11] and an estimated
life expectancy of ≥12 weeks.
Key exclusion criteria included inability to swallow tab-
lets; inability to discontinue phenytoin, carbamazepine, and
phenobarbital; clinically significant cardiac disease; central
nervous system metastases or tumor; evidence of bleeding
diathesis or coagulopathy, or requirement for concurrent
systemic anticoagulation; and history of major surgery, open
biopsy, or significant traumatic injury within 28 days of
treatment.
This study was conducted in accordance with the decla-
ration of Helsinki and applicable good clinical practice
guidelines. Human investigations were performed after ap-
proval by a local Human Investigations Committee and in
accordance with an assurance filed with and approved by
the Department of Health and Human Services. Written
informed consent was obtained according to federal and
local guidelines.
Study design and treatment
This was a single-center, open-label, nonrandomized, dose-
escalating phase I trial. The objectives were to: determine
the recommended phase II doses (RP2D) of enzastaurin and
bevacizumab; characterize toxicities; document antitumor
activity; evaluate PK; and assess phosphorylated GSK3-β
(pGSK3-β) as a biomarker of enzastaurin. Because pharma-
cokinetic exposure variation was expected, cohorts of 6
were utilized. Planned enrollment was 66 patients.
Figure 1 shows the study design. Each cohort enrolled 3
patients; if ≤1 dose-limiting toxicity (DLT) occurred, an
additional 3 patients were enrolled in that cohort and dose
escalation continued. The maximum tolerated dose (MTD)
was achieved when 2 DLTs occurred in any given dose
level; dose escalation then ceased, and the prior dose level
was defined as the RP2D of the combination.
All patients continued on study drug therapy until pro-
gressive disease (PD), unacceptable toxicity, or other dis-
continuation criterion emerged. Once discontinued, patients
were followed for 30 days following their last enzastaurin
dose, or until they received another antitumor therapy.
Patient evaluations
Adverse events (AEs) were assessed using National Cancer
Institute Common Terminology Criteria for Adverse Events
(NCI CTCAE version 3.0) criteria. Hematologic DLTs were:
grade 4 neutropenia for ≥7 days; febrile neutropenia; and
grade 3 thrombocytopenia with bleeding or grade 4 throm-
bocytopenia. Nonhematologic DLTs were: grade 3 or grade
4 toxicities; grade 4 hypertension; uncontrollable grade 3
hypertension; grade 4 hemorrhage; hemorrhage requiring
discontinuation; any arterial thromboembolic event; grade
4 venous thrombosis; congestive heart failure; grade 4 pro-
teinuria; gastrointestinal perforation, leak or fistula; grade 3
or grade 4 bowel obstruction; wound dehiscence requiring
intervention; and grade 3 or 4 anaphylactic reactions to
bevacizumab.
Tumor responses were assessed using RECIST guidelines
[11]. Lesion assessments were repeated using the same meth-
ods as baseline. Tumor assessments by physical examination
were performed prior to each cycle, whereas radiologic tumor
assessments were done prior to every other cycle.
Pharmacokinetic methods
Plasma concentration-time data from intensive sampling
were used to calculate PK parameters for enzastaurin and
the major active metabolite LY326020 on cycle 2 day 1 and
bevacizumab on cycle 1 day 1. Enzastaurin and LY326020
samples were analyzed at Advion BioServices, Inc. (Ithaca,
NY) using validated tandem liquid chromatography mass
spectrometry. Bevacizumab samples were analyzed at Inter-
tek (ALTA Analytical Laboratory, San Diego, CA) using a
validated enzyme-linked immunosorbent assay (ELISA).
Standard non-compartmental methods (WinNonlin® En-
terprise, Version 5.3) were used to calculate PK parameters.
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The average concentration at steady state (Cav,ss) was
determined for enzastaurin and LY326020. The area under
the plasma concentration–versus-time curve from time zero
to infinity (AUC[0-∞]) was determined for bevacizumab.
Biomarker (GSK3-β) analysis
Levels of pGSK3-β in peripheral blood mononuclear cells
(PBMCs) were measured using an ELISA assay by Milli-
pore (Billerica, MA). The pGSK3-β levels were normalized
by the protein content of the sample.
Statistical analysis
Evaluation of RP2D was conducted for all patients receiving
≥1 cycle of study medication and for patients who did not
complete 1 cycle but experienced a DLT. Safety and PK
analyses were performed for all patients receiving ≥1 dose
of study drug. Antitumor activity was described using best
overall response and time to tumor progression (TTP).
Kaplan-Meier survival functions were estimated. Changes
in pGSK3-β level from baseline were explored using a
mixed-model repeated measures (MMRM) analysis with




From January 2007 to August 2009, 67 patients at Johns
Hopkins Kimmel Cancer Center received ≥1 dose of study
drug. Table 1 shows baseline demographics.
Safety
The median delivered enzastaurin dose was 698 mg/d
(range, 464 to 1938 mg/d); this was 99 % (range, 16 % to
100 %) of the planned dose. The median bevacizumab dose
was 10 mg/kg (range, 5 to 19); this was 100 % of the
planned dose. The mean±standard deviation number of
received cycles was 8±10.
Six patients experienced 1 DLT each during cycle 1.
The DLTs were grade 3 fatigue (n04; cohorts 2c, 2d,
3d), grade 4 cerebral hemorrhage (n01; cohort 2b), and
grade 3 elevated aspartate transaminase at dose level 2
(n01). Two patients in cohort 2d experienced DLTs
(grade 3 fatigue), thus defining the MTD. Consequently,
the RP2 doses of enzastaurin were all preceding dose
levels: 500 mg QD or 250, 375, or 500 mg BID, with
bevacizumab 5 mg/kg or 10 mg/kg every 14 days, or
15 mg/kg every 21 days.
Eleven patients (16.4 %) experienced ≥1 serious ad-
verse event (SAE) that was considered drug-related (see
Online Resource 1, footnote b). At least 66 patients
experienced a drug-related AE. Drug-related AEs (all
grades) occurring in >20 % of patients were: urine color
change (86.6 %), fatigue (68.7 %), gastrointestinal -
other (52.2 %; mostly fecal discoloration), diarrhea
(49.3 %), pain (47.8 %), nausea (41.8 %), pulmonary/
upper respiratory hemorrhage (31.3 %), constipation
(29.9 %), anorexia (26.9 %), abdominal distention/bloat-
ing (23.9 %), and vomiting (20.9 %). Online Resource 1
shows drug-related grades 3 through 5 AEs.
Fourteen patients discontinued due to AEs, of which
12 were serious. Nine discontinuations were from drug-
related AEs, of which 7 were serious (grade 3 elevated
aspartate transaminase and alanine transaminase; grade 4
cerebral hemorrhage; grade 3 failure to thrive; grade 4
genital tract fistula; grade 4 myocardial infarction; grade
3 thrombosis; and grade 3 pulmonary embolism). Each
of the AEs and SAEs causing discontinuation occurred
once. Six patients died during the trial; 2 deaths oc-
curred on treatment, and 4 occurred within 30 days of
treatment cessation. Of the 2 on-treatment deaths, 1 was
from PD (cycle 4), and the second (ventricular tachy-
cardia; cycle 1) was retrospectively considered possibly
drug-related and confounded by PD. This patient with
spinal involvement and potentially brain metastases, ex-
perienced a seizure-like situation and cardiac arrest with
ventricular tachycardia on ECG. This event was not
considered a DLT because the patient’s disease had
progressed, and death more likely stemmed from central
nervous system involvement rather than from study
drug. Of the 4 deaths occurring after treatment, 1 was
thought to be bevacizumab-related (cerebral hemorrhage;
cycle 1), and 3 were due to PD.
Pharmacokinetics
Table 2 shows the enzastaurin, LY326020, and bevacizumab
PK results. When enzastaurin was administered as 500 mg
daily, the mean Cav,ss of enzastaurin and LY326020 were
similar across bevacizumab schedules. A dose-dependent
increase in the enzastaurin mean Cav,ss was seen across the
250- to 750-mg BID dose range when enzastaurin was given
with 10 or 15 mg/kg bevacizumab.
The mean AUC(0-∞) for patients receiving bevacizumab
10 mg/kg ranged from 1740 μg·day/mL to 2360 μg·day/mL,
Efficacy
Of the 67 enrolled patients, 19.4 % (95 % confidence interval
[CI], 10.8 % to 30.9 %) responded to treatment (com-
plete response, 9 %; partial response, 10.4 %) (Table 3).
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Complete responses were experienced by patients with
ovarian (n04), esophageal (n01), and neuroendocrine
tumors (n01), and partial responses were experienced
by patients with ovarian (n06) and uterine papillary (n01)
cancers.
Table 3 also shows measured time to event parameters in
the entire cohort and ovcar subgroup per dose level.
GSK3-β analysis
PBMC samples from 54 treated patients were evaluable for
pGSK3-β. Online Resource 2 shows estimated mean
pGSK3-β over time by dose schedule, which suggests a
decreasing trend of pGSK3-β from baseline in both QD
and BID schedules. However, the MMRM analysis did not
suggest a statistically significant difference in pGSK-β de-
cline over time between the 2 dosing schedules.
Discussion
To determine the RP2D of enzastaurin and bevacizu-
mab, this trial evaluated several dosing and scheduling
regimens. Enzastaurin BID dosing was investigated
because this schedule modestly increases exposures rel-
ative to QD dosing without clinically significant wors-
ening of toxicities in most patients [6]. Oral enzastaurin
(500 mg QD or 250, 375, or 500 mg BID), together
with bevacizumab (5 mg/kg or 10 mg/kg every 14 days,
Table 1 Baseline patient
demographics
ECOG Eastern Cooperative On-
cology Group
Characteristic All Patients (N067) Ovarian Cancer Subset (n031)
Median age (range), years 61.3 (23.3 to 84.6) 60.5 (23.3 to 73.7)
Gender
Female 49 (73.1) 31 (100.0)
Male 18 (26.9) –
Origin
Caucasian 59 (88.1) 26 (83.9)
African-American 4 (6.0) 1 (3.2)
Asian 1 (1.5) 1 (3.2)
Not reported/unknown 3 (4.5) 3 (9.7)
ECOG Performance Status, n (%)
0 45 (67.2) 25 (80.7)
1 22 (32.8) 6 (19.3)
Tumor type, n (%)
Bladder 3 (4.5) –
Breast 3 (4.5) –
Esophagus 2 (3.0) –
Kidney 2 (3.0) –
Ovarian 31 (46.3) 31 (100.0)
Parotid 2 (3.0) –
Peritoneal 5 (7.5) –
Prostate 6 (9.0) –
Uterine papillary 2 (3.0) –
Other 11 (16.4) –
Prior therapies, n (%)
At least 1 prior 66 (98.5) 30 (96.8)
Surgery 52 (77.6) 25 (80.7)
Radiotherapy 16 (23.9) 1 (3.2)
Chemotherapy 61 (91.0) 30 (96.8)
Immunotherapy 6 (9.0) 1 (3.2)
Hormonal 6 (9.0) 3 (9.7)
Supportive 1 (1.5) 0 (0.0)
Fig. 1 Study design. Dosing of the cohorts is shown. BID, twice daily;
BV, bevacizumab; DLT, dose-limiting toxicity; ENZ, enzastaurin; IV,
intravenous; PO, oral; QD, once daily. * All cohorts subsequent to
Dose Level 1 followed the same enrollment pattern and safety assess-
ment schedule shown in Dose Level 1
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or 15 mg/kg every 21 days) are well tolerated. The
highest enzastaurin dose (750 mg BID) resulted in 4
DLTs (severe fatigue), with 2 occurring in cohort 2d
(Fig 1), thus defining the MTD.
The combination of enzastaurin and bevacizumab did not
appear to alter or exacerbate the AE profiles that have been
observed when either drug was given alone. The majority of
enzastaurin-related AEs observed here were consistent with
those observed in another enzastaurin monotherapy study
[5]. Other AEs were consistent with previous observations
for bevacizumab [12].
The enzastaurin and LY326020 mean Cav,ss are sim-
ilar to historical estimates for 250 mg BID (500 mg/d)
and 500 mg QD [7, 9]. This study showed no evidence
that the Cav,ss of enzastaurin or LY326020 were affected
by bevacizumab (5, 10, or 15 mg/kg). Enzastaurinmean
Cav,ss increases in a dose-dependent fashion when enzas-
taurin is dosed from 250 mg to 750 mg BID.
Table 2 Pharmacokinetics of enzastaurin and bevacizumab
Cav,ss of Enzastaurin and LY326020 (Geometric Mean [CV %])*
Bevacizumab Dose 5 mg/kg 10 mg/kg 15 mg/kg
500 mg QD
N 3 1a 2a
Enzastaurin 673 (25) 393 (NC) 1200, 678 (NC)
LY326020 596 (37) 744 (NC) 609, 718 (NC)
250 mg BID
N – 6 4
Enzastaurin – 557 (117) 503 (78)
LY326020 – 527 (178) 812 (61)
375 mg BID
N – 4 6
Enzastaurin – 1030 (66) 1110 (112)
LY326020 – 1200 (22) 1060 (45)
500 mg BID
N – 4 4
Enzastaurin – 1400 (77) 1460 (125)
LY326020 – 990 (66)b 1220 (35)
750 mg BID
N – – 4
Enzastaurin – – 2660 (118)
LY326020 – – 1420 (58)b
Bevacizumab Exposure (Geometric Mean [CV %])**
Enzastaurin Dosing Regimen 500 mg QD 250 mg BID 375 mg BID 500 mg BID 750 mg BID
Bevacizumab 5 mg/kg
N
6 – – – –
AUC(0-∞) 848 (63) – – – –
Bevacizumab 10 mg/kg
N 6 6 3 5 2a
AUC(0-∞) 2360 (17) 1770 (43) 1740 (5) 1770 (22) 1570, 1600 (NC)
Bevacizumab 15 mg/kg
N 5 5 6 5 3
AUC(0-∞) 2250 (42) 2590 (45) 1640 (26) 2080 (25) 1820 (19)
AUC(0-∞) area under the concentration-versus-time curve from zero to infinity; BID twice daily; Cav,ss average drug concentration at steady state; CV
coefficient of variation; N number of patients with calculable estimates; NC not calculable; QD once daily; (–) no data in group
* Cav,ss (nmol/L) of enzastaurin and LY326020 from cycle 2, day 1 following once- or twice-daily dosing of enzastaurin with bevacizumab
**Bevacizumab AUC(0-∞) (μg·day/mL) estimates from cycle 1, day 1 following an intravenous infusion of bevacizumab with enzastaurin
a Insufficient data to calculate mean, individual parameter estimates listed
bN03
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Although AUC(0-∞) reported here for bevacizumab
appears lower than in 2 historical studies [13, 14], no PK
interaction is anticipated between enzastaurin and bevacizu-
mab. Enzastaurin is primarily metabolized by CYP3A [5],
whereas bevacizumab, a monoclonal antibody, is likely
metabolized by the reticuloendothelial system[15]. The cur-
rent study did not have a bevacizumab-only arm, so it is
unknown whether the apparent difference in mean AUC(0-∞)
is due to enzastaurin co-administration or simply a conse-
quence of interstudy variability.
The response rate in this trial was higher than that
reported in our previous phase I trial involving patients with
advanced cancer [5]. Patients receiving BID treatment ex-
perienced a higher rate of disease stabilization than those
receiving QD treatment, and patients with ovcar seemed to
fare better than expected.
The combination of enzastaurin and bevacizumab was
previously tested in a phase II trial involving patients with
recurrent glioblastoma [16]. Although the combination was
well tolerated and exhibited clinical activity, it did not appear
to improve clinical outcomes relative to bevacizumab mono-
therapy. In contrast, the combination of enzastaurin and bev-
acizumab therapy appears to have delayed disease progression
in the ovcar subset relative to results published for bevacizu-
mab monotherapy [10, 17] and 500 mg QD enzastaurin
monotherapy in patients with ovcar [18]. This suggests that
the combination may have a unique effect on ovarian tumors;
however, it should be noted that the BID dosing schedule of
enzastaurin may have provided an exposure advantage rela-
tive to the glioblastoma study, which used QD dosing [16].
The promising results for the ovcar subset should be viewed
cautiously due to the small number of heterogeneous patients.
Thus, further confirmatory studies are needed.
The activity of GSK3-β is inhibited by PKB/AKT-dependent
phosphorylation [19] and thus, is a potential biomarker of
enzastaurin activity [2]. On average, pGSK3-β levels were
decreased from baseline in both schedules, with a maximum
occurring at treatment discontinuation. However, no statistically
Table 3 Summary of efficacy
Variable All Patients (N067) Ovarian Cancer (N031)
All QD BID All QD BID
N067 n018 n049 N031 n07 n024
Response rate, n (%)a 13 (19.4) 6 (33.3) 7 (14.3) 10 (32.3) 4 (57.1) 6 (25.0)
95 % CIb 10.8 to 30.9 13.3 to 59.0 5.9 to 27.2 16.7 to 51.4 18.4 to 90.1 9.8 to 46.7
Best overall response, n (%)
Complete response 6 (9.0) 5 (27.8) 1 (2.0) 4 (12.9) 3 (42.9) 1 (4.2)
Partial response 7 (10.4) 1 (5.6) 6 (12.2) 6 (19.4) 1 (14.3) 5 (20.8)
Stable disease 29 (43.3) 5 (27.8) 24 (49.0) 14 (45.2) 1 (14.3) 13 (54.2)
Progressive disease 13 (19.4) 7 (38.9) 6 (12.2) 3 (9.7) 2 (28.6) 1 (4.2)
Not assessed 12 (17.9) 0.0 (0.0) 12 (24.5) 4 (12.9) 0.0 (0.0) 4 (16.7)












Median duration of stable disease








(3.7 to 5.5) –
4.0
(3.7 to 11.3)
6-month rate of duration
(95 % CI)
27.3




(3.4 to 43.4) –
25.2
(3.8 to 46.6)
Median time to disease progression or death




















(32.4 to 68.4) –
52.6
(32.0 to 73.2)
CI confidence interval; CR complete response; PD progressive disease; PR partial response; RECIST Response Evaluation Criteria in Solid Tumors;
SD stable disease
a Defined as the proportion of patients achieving a CR plus PR using RECIST version 1.0
b 95 % CI based on exact binomial probabilities
cMeasured from the date that measurement criteria are met for CR or PR until the first date of documented PD. Duration of response was censored
at the date of the last assessment visit for responders with no evidence of PD
dMeasured from the date of the first dose until the first date of PD. Duration of SD was censored at the date of the last assessment visit for patients
with SD with no evidence of PD
eDefined as the time from the date of the first enzastaurin or bevacizumab dose to the first date of PD. Time to disease progression was censored at
the date of the last assessment visit for patients with no evidence of PD. Estimated using the Kaplan-Meier method
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significant difference in mean pGSK3-β across time was found
possibly related to large interpatient variability. The decline of
pGSK3-β levels with enzastaurin exposure time is consistent
with previous findings, suggesting that the pGSK3-β inhibitory
effects in PBMCs are a component of the antitumor activity of
enzastaurin [2]. The pGSK3-β results are exploratory in nature
and warrant further confirmatory studies.
In conclusion, this study showed no evidence that the PK
of enzastaurin or LY326020 were affected when enzastaurin
was administered with bevacizumab (5, 10, or 15 mg/kg). The
observed antitumor activity in patients receiving both enzas-
taurin and bevacizumab was higher than that reported in our
previous phase I trial involving patients with advanced cancer
[5], with outcomes (median duration of stable disease; median
TTP) appearing to favor the BID enzastaurin dosing groups.
Combination therapy showed limited but potentially encour-
aging efficacy results in ovcar patients, but we cannot exclude
the possibility that the observed activity is due to bevacizumab
alone. The observed benefit should be confirmed in subse-
quent controlled trials and suggests that PI3K/AKT inhibition
in combination with anti-VEGF therapy may be worth pursu-
ing in patients with ovcar.
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